Quest joins breast cancer gene-testing market

Share this article:

Quest's new BRCA test may loosen Myriad's hold on the genetic cancer testing market. The diagnostics firm is now selling tests for the two cancer genes that are linked to breast and ovarian cancer—BRCA1 and BRCA2—and for which Medicare pays around $3,400 when using Myriad's version. Bloomberg reports that Quest plans on charging $2,500.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions